药明生物(02269.HK)配售4650万股一级配售股份 净筹39.29亿港元
格隆汇11月1日丨药明生物(02269.HK)公布,于10月31日,配售代理与公司订立一级配售协议,据此,配售代理向目前预期不少于六名的独立专业、机构及╱或其他投资者按悉数包销基准及每股85.00港元(较收市价每股92.50港元折让约8.11%)的价格配售4650万股一级配售股份。
假设于公告日期至一级配售完成公司已发行股本不会发生任何变动,4650万股一级配售股份相当于(i)公司于公告日期现有已发行股本约3.73%;及(ii)公司经配发及发行一级配售股份扩大的已发行股本约3.60%。一级配售股份的总面值将为1,162.5美元。
公告称,所得款项净额将约为39.29亿港元及每股一级配售股份的净价将约为84.80港元。公司拟将一级配售的所得款项净额用于支持其疫苗及微生物产品开发以及继续进行全球产能扩张,包括其位于美国、欧洲及中国的设施,以满足集团客户日益增长的需求。
此外,于10月31日,董事会获公司的其中一名控股股东Biologics Holdings知会,其已与配售代理订立二级配售协议,据此,配售代理按每股85.00港元的价格向独立第三方配售Biologics Holdings持有的4650万股二级配售股份,相当于公司于公告日期已发行股本约3.73%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.